Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Minerva Surgical to $1 from $5 and keeps an Overweight rating on the shares following the Q1 sales beat. With the company having addressed its near-term financing issue, continued sales momentum "should help reinvigorate sentiment on the name," the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on UTRS:
- Minerva Surgical Reports First Quarter 2023 Financial Results
- UTRS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Minerva Surgical to Announce First Quarter 2023 Financial Results
- Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer
- Minerva Surgical Reports Fourth Quarter and Full-Year 2022 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue